CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate.

ABSTRACT: Background: Glatiramer acetate (GA) is an effective treatment for the earliest stages of multiple sclerosis (MS)-clinically isolated syndrome (CIS) or clinically definite MS (CDMS). Objective: This study aims to determine the differences in the lymphocyte population (at baseline and the course of five years) between confirmed sustained progression (CSP) and non-CSP groups and to identify potential biomarkers among these parameters that can predict a positive response to the treatment. Methods: Twelve male and 60 female patients were included in the study. Peripheral blood samples were collected before and five years after treatment with GA. The authors compared lymphocyte parameters between the CSP and non-CSP groups by statistical analyses. Univariate and penalized logistic regression mod

SUBMITTER: Valis M 

PROVIDER: S-EPMC6562382 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature